CA
NZ
UK
AU
IND
US
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc, filed a statement of changes in beneficial ownership on August 25, 2026, reporting an acquisition of deferred stock units dated August 21, 2026.
Robert M. VanHimbergen, Executive Vice President and CFO of Elanco Animal Health Incorporated, filed a statement of changes in beneficial ownership on August 25, 2026, reporting the acquisition of deferred stock units on August 21, 2026.
Ronald A. Brack, Executive Vice President, Chief Accounting Officer and Controller of GEO Group Inc, filed a statement of changes in beneficial ownership on August 25, 2026, reporting a sale of common stock and disclosing a prior share transfer tied to a domestic relations …
August J. Troendle, President and CEO of Medpace Holdings, Inc., filed a Form 4 on August 25, 2026, disclosing the sale of common stock on August 21 and August 24, 2026, traded on NASDAQ:MEDP.
A Form 4 filed on August 25, 2026 reports that David Nicholas Gee, Chief Marketing Officer of Cellebrite DI Ltd. (NASDAQ:CLBT), sold 4,323 ordinary shares on August 24, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
Sean Jack Buckley, Chief People & Systems Officer at Roblox Corp (NYSE:RBLX), filed a Form 4 on August 25, 2026, reporting the sale of 4,321 shares of Class A Common Stock on August 24, 2026.
Ross Curtis, Executive Vice President and Chief Portfolio Officer of RenaissanceRe Holdings Ltd, filed a Form 4 on August 25, 2026, disclosing the sale of 5,000 shares of common stock on August 24, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Ryan Fukushima, CEO of Data at Tempus AI, Inc. (NASDAQ:TEM), filed a Form 4 on August 25, 2026, disclosing a sale of 14,286 shares of Class A Common Stock on August 21, 2026, executed under a Rule 10b5-1 trading plan.
Johannes Jacob Pieter Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), filed a Form 4 on August 25, 2026, reporting the exercise of options and sale of 125,000 ordinary shares on August 24, 2026, pursuant to a pre-established Rule 10b5-1 …
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, Inc., filed a Form 4 on August 25, 2026, disclosing a sale of Class A Common Stock executed on August 21, 2026, under a pre-established Rule 10b5-1 trading plan.
Please wait processing your request...